Neurocrine to buy Soleno Therapeutics for $2.9 billion
- Posted on April 6, 2026
- By CNBC
- 0 Views
Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
